ATHE
Alterity Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · AU
$2.44
−1.21%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.47
From 52W high−58.57%
Volume120498.00
Market cap$46.58M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.47
From 52W high
−58.57%
Volume
120498.00
Market cap
$46.58M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
45.1
MomentumView details →
1D Return
−1.21%
YTD Return
−16.88%
SummaryUpdated Jun 1, 2026
Alterity Therapeutics Limited (ASX:ATHE) is an Australian biotechnology company founded in 1997 and headquartered in Melbourne. Originally incorporated as Prana Biotechnology Limited, the company rebranded to its current name in April 2019. Alterity focuses on developing therapeutic drugs to treat neurodegenerative diseases, particularly Alzheimer's disease, Huntington's disease, Parkinson's disease, and other neurological disorders. As a clinical-stage biotechnology company, Alterity has been publicly traded since 2003 and represents the emerging field of precision medicine targeting neurodegeneration through novel therapeutic approaches.
Similar companies
Latest newsMore news →
ALTERITY THERAPEUTICS LTD reported a cash balance of A$41.3 million as of 30 September 2026, including an A$3.98 million Australian R&D Tax Incentive refund and approximately A$5.5 million net raised through exercise of listed options.6d agoAlterity Therapeutics presented new analyses of ATH434 Phase 2 data in multiple system atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders, reporting that ATH434 50 mg slowed functional decline by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate.31d ago